Retmarker S.A. (Meteda Company)

Our objective, to build a valuable global business on affordable healthcare for retinal diseases, relies on the Retmarker Technology and Operating Model. Retmarker, a patented and certified medical device, is a biomarker for Diabetic Retinopathy progression. Diabetic Retinopathy is the eye-sight complication of Diabetes (382 Million today and 592 Millions estimated in 2035) and the leading cause of blindness in the working population. To avoid blindness, all Diabetics should be screened at least once a year in order to provide early and timely treatment. Retmarker has been used with success in Diabetic Retinopathy Screening Programs since 2011. The aim of Retmarker is not to replace doctors and specialists, rather to provide efficient solutions that empower them to provide the best healthcare to those threatened by Diabetic Retinopathy.